GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenaya Therapeutics Inc (NAS:TNYA) » Definitions » EPS without NRI

Tenaya Therapeutics (Tenaya Therapeutics) EPS without NRI : $-1.64 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tenaya Therapeutics EPS without NRI?

Tenaya Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.40. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.64.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Tenaya Therapeutics's EPS without NRI or its related term are showing as below:

TNYA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41.8   Med: -23.9   Max: -6
Current: -6

During the past 5 years, Tenaya Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -6.00% per year. The lowest was -41.80% per year. And the median was -23.90% per year.

TNYA's 3-Year EPS without NRI Growth Rate is ranked worse than
63.99% of 1297 companies
in the Biotechnology industry
Industry Median: 5.5 vs TNYA: -6.00

Tenaya Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.40. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.64.

Tenaya Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.40. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.64.


Tenaya Therapeutics EPS without NRI Historical Data

The historical data trend for Tenaya Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenaya Therapeutics EPS without NRI Chart

Tenaya Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
-0.97 -1.41 -4.10 -2.76 -1.68

Tenaya Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.43 -0.45 -0.39 -0.40 -0.40

Competitive Comparison of Tenaya Therapeutics's EPS without NRI

For the Biotechnology subindustry, Tenaya Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenaya Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's PE Ratio without NRI falls into.



Tenaya Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tenaya Therapeutics  (NAS:TNYA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Tenaya Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Tenaya Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenaya Therapeutics (Tenaya Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Executives
Timothy Hoey officer: Chief Scientific Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080
Leone D Patterson officer: Chief Fin and Bus. Officer
Whittemore Tingley officer: Chief Medical Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Faraz Ali director, officer: Chief Executive Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Amy L. Burroughs director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Deepak Srivastava director C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019

Tenaya Therapeutics (Tenaya Therapeutics) Headlines

From GuruFocus

Tenaya Therapeutics Announces Closing of Public Offering

By Value_Insider Value_Insider 11-21-2022

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

By Stock market mentor Stock market mentor 01-09-2023

Tenaya Therapeutics Announces Closing of Public Offering

By GlobeNewswire GlobeNewswire 11-21-2022